SRPT (Sarepta Therapeutics) Change In Receivables: $150 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SRPT Sarepta Therapeutics Inc SRPT
53 GF Score
Price $18.13
GF Value $109.19
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Sarepta Therapeutics Change In Receivables?

Sarepta Therapeutics SRPT -3.51% 53 Change In Receivables is $150 Mil as of Jun. 2026. GuruFocus rates SRPT with a GF Score™ of 53/100 and a GF Value™ of $109.19 (Possible Value Trap). The stock has 3 warning signs investors should review.

Sarepta Therapeutics's change in receivables for the quarter that ended in Jun. 2026 was $18 Mil. It means Sarepta Therapeutics's Accounts Receivable declined by $18 Mil from Mar. 2026 to Jun. 2026 .

Sarepta Therapeutics's change in receivables for the fiscal year that ended in Dec. 2025 was $204 Mil. It means Sarepta Therapeutics's Accounts Receivable declined by $204 Mil from Dec. 2024 to Dec. 2025 .

Sarepta Therapeutics's Accounts Receivable for the quarter that ended in Jun. 2026 was $377 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Sarepta Therapeutics's Days Sales Outstanding for the three months ended in Jun. 2026 was 85.69.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Sarepta Therapeutics's liquidation value for the three months ended in Jun. 2026 was $-137 Mil.

Sarepta Therapeutics  (NAS:SRPT) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Sarepta Therapeutics's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=376.824/401.251*91
=85.69

2. In Ben Graham's calculation of liquidation value, Sarepta Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Sarepta Therapeutics's liquidation value for the quarter that ended in Jun. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=788.489-1660.714+0.75 * 376.824+0.5 * 904.273
=-137

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sarepta Therapeutics Change In Receivables Related Terms

Sarepta Therapeutics Change In Receivables Historical Data

* Premium members only.

The historical data trend for Sarepta Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sarepta Therapeutics Change In Receivables Chart

Sarepta Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -51.65 -61.64 -185.70 -201.66 203.76

Sarepta Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 132.08 131.56 -2.49 3.42 17.99
SRPT
53GF Score
Sarepta Therapeutics Inc SRPT
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sarepta Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $150 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of $150 Mil mean?
Sarepta Therapeutics (SRPT) has a Change In Receivables of $150 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Sarepta Therapeutics and its competitors.
Is Sarepta Therapeutics' Change In Receivables too high?
Sarepta Therapeutics' current Change In Receivables is $150 Mil. Overall, Sarepta Therapeutics has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sarepta Therapeutics' Change In Receivables compare to MPLT and ZYME?
Sarepta Therapeutics' Change In Receivables of $150 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Sarepta Therapeutics and its competitors. Sarepta Therapeutics's current Change In Receivables is $150 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sarepta Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Sarepta Therapeutics (SRPT) is currently considered Possible Value Trap. The stock's GF Value™ is $109.19, compared to a current price of $18.13 — trading 83.4% below its estimated fair value. The current Change In Receivables is $150 Mil. Sarepta Therapeutics' overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Sarepta Therapeutics (SRPT), the current Change In Receivables is $150 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sarepta Therapeutics (SRPT) Overvalued in 2026?

Based on GuruFocus' analysis, Sarepta Therapeutics stock appears to be undervalued. The current stock price of $18.13 is trading 83.4% below its estimated GF Value™ of $109.19. GuruFocus considers Sarepta Therapeutics to be Possible Value Trap.

Key valuation signals for SRPT:

  • Change In Receivables: $150 Mil
  • GF Value™: $109.19 vs. price of $18.13 (83.4% below fair value)
  • GF Score™: 53/100 with 3 warning signs

No single metric tells the full story. See the SRPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sarepta Therapeutics Business Description

Address 215 First Street, Suite 415, Cambridge, MA, USA, 02142
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
53GF Score

Get the complete analysis for SRPT

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.13
Price
$109.19
GF Value